- Home
- URGN vs MUE Comparison
URGN vs MUE Comparison
Compare URGN & MUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MUE
- Stock Information
- Founded
- URGN 2004
- MUE 1999
- Country
- URGN United States
- MUE United States
- Employees
- URGN N/A
- MUE N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MUE Investment Bankers/Brokers/Service
- Sector
- URGN Health Care
- MUE Finance
- Exchange
- URGN Nasdaq
- MUE Nasdaq
- Market Cap
- URGN 181.2M
- MUE 208.4M
- IPO Year
- URGN 2017
- MUE N/A
- Fundamental
- Price
- URGN $13.84
- MUE $9.58
- Analyst Decision
- URGN Strong Buy
- MUE
- Analyst Count
- URGN 8
- MUE 0
- Target Price
- URGN $29.00
- MUE N/A
- AVG Volume (30 Days)
- URGN 4.3M
- MUE 62.6K
- Earning Date
- URGN 08-12-2025
- MUE 01-01-0001
- Dividend Yield
- URGN N/A
- MUE 4.09%
- EPS Growth
- URGN N/A
- MUE N/A
- EPS
- URGN N/A
- MUE N/A
- Revenue
- URGN $91,871,000.00
- MUE N/A
- Revenue This Year
- URGN $36.65
- MUE N/A
- Revenue Next Year
- URGN $88.35
- MUE N/A
- P/E Ratio
- URGN N/A
- MUE N/A
- Revenue Growth
- URGN 8.98
- MUE N/A
- 52 Week Low
- URGN $3.42
- MUE $8.53
- 52 Week High
- URGN $18.15
- MUE $10.17
- Technical
- Relative Strength Index (RSI)
- URGN 64.90
- MUE 51.64
- Support Level
- URGN $13.26
- MUE $9.51
- Resistance Level
- URGN $13.94
- MUE $9.65
- Average True Range (ATR)
- URGN 0.91
- MUE 0.07
- MACD
- URGN -0.08
- MUE 0.01
- Stochastic Oscillator
- URGN 44.44
- MUE 70.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.